Quick Search:         Advanced Search
Chinese Version
Online office
Journal Online
Download
Top
Links
郭兴伯,符林春,符永新,林军章,苏海妹,谢带嫦,李国桥.青蒿素栓与磷酸喹哌治疗恶性疟的对照观察[J].,1989,(8):475-477,453
青蒿素栓与磷酸喹哌治疗恶性疟的对照观察
Comparative Study of Artemisinin Suppositories and Piperaquine Phosphate in Treatment of Falciparum Malaria
  
DOI:
中文关键词:  恶性疟原虫  磷酸喹哌  青蒿素栓  治疗  复燃  碱性磷酸酶  给药方案  毒副反应  实验室检查  白细胞计数
英文关键词:
基金项目:
Author NameAffiliation
Guo Xingbo 广州中医学院热带病研究所 
Fu Linchun 广州中医学院热带病研究所 
符永新 广州中医学院热带病研究所 
林军章 广州中医学院热带病研究所 
苏海妹 广州中医学院热带病研究所 
谢带嫦 广州中医学院热带病研究所 
李国桥 广州中医学院热带病研究所 
Hits: 1416
Download times: 904
中文摘要:
      本文采用青蒿素栓3天疗程成人总量2800mg 治疗恶性疟65例,并随机设磷酸喹哌对照组进行比较。其原虫转阴时间(71.8±16.0h)显著快于磷酸喹哌组(100.3±20.3h),但28天原虫复燃率(48.2%)非常显著高于磷酸喹哌组(17.0%)。青蒿素栓使用简便,适用于农村边远疟区和不能口服的患者。
英文摘要:
      Artemisinin developed by Chinese scientists,is a new type of anti-malaclal drug with quick effect and low toxicity.Since its solubility in water or oil is very low,it cannot be made into a clear injection to be given intramuscularly or intravenously for emergency use.The Artemisinin supposi- tories used in the study was provided by the institute of Chinese Mataeria Medial in 1982.Phase Ⅰ and Phase Ⅱ clinical trials of the drug were made by Guangzhou College of TCM.The results showed that the therapeutic effect of Artemisinin suppositories was satisfactory with no apparent side effects.The total dosage recommended was 2800~3200 mg.In 1986,fifty-six adults with falciparum malaria were treated with a total dose of 2800 mg Artemisinin suppositories for 3 days and randomly compared with a control group of Piperaquine phosphate in the Dongfang(东方)Town Hospital, Dongfang County of Hainan Island.The parasite clearance time in Artemisinin suppositories group (71.8±16.0 hrs)was significantly faster than that of Piperaquine phosphate group(100.3±20.3hrs),but recrudescence rate by 28 days(48.2%)was much higher than that of Piperaquine phosphate(17.0%). Artemisinin suppositories is simple to administrate and therefore it could be applied in endemic area of remote countryside and to the patients of incapable of oral dosing.
View Full Text  View/Add Comment  Download reader